The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...

Bristol Myers Squibb partners with BioNTech in a $11.1B deal to develop BNT327, a promising cancer immunotherapy. Read more ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

The birds amassed fans, as legions of devotees follow along on webcams each spring as falcons progress from hatching to ...

Science Connected Magazine is an editorially independent, non-profit newsroom producing open-access science journalism and scientific fact-checking for the global public.

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Data to be presented at ASCO reflect Boehringer's broad pipeline and growing body of evidence supporting innovative therapies for various cancersPatient-reported outcomes from the Beamion LUNG-1 study ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...

Zura Bio has launched the randomised Phase II TibuSHIELD trial assessing tibulizumab in the adult population with moderate to ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

2025 marks the 25th anniversary of All Saints’ chart-topping '00s classic Pure Shores ... To help you understand how it works, I reconstructed the organ and “guitar” parts in the intro in Ableton Live ...

DNA reveals what skin color obscures: We all have African ancestors ... groups began to move to different parts of the continent and become isolated from one another—in effect founding new ...